Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-09-17 21:29:21 ET · period of report 2026-09-15 · accession 0001882909-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 21:29 | 2026-09-15 | TVTX | Calvin Sandra | SVP, CAO | M - OptEx | $24.19 | +5,375 | 47.7K | +13% | +$130.0K |
| DMT | 2026-09-17 21:29 | 2026-09-15 | TVTX | Calvin Sandra | SVP, CAO | S - Sale+OE | $62.33 | -5,375 | 42.4K | -11% | -$335.0K |
| DMT | 2026-09-17 21:29 | 2026-09-15 | TVTX | Calvin Sandra | SVP, CAO | M - OptEx | $0.00 | -5,375 | 17.9K | -23% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 2,500 | $27.50 | 44,853 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-15 | M | A | 1,250 | $22.40 | 46,103 | D | — | — | |
| 3 | Common | Common Stock | 2026-09-15 | M | A | 1,625 | $20.46 | 47,728 | D | — | — | |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 4,275 | $62.13 | 43,453 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F2) The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2026-09-15 | S | D | 800 | $62.85 | 42,653 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F3) The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 6 | Common | Common Stock | 2026-09-15 | S | D | 300 | $63.66 | 42,353 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F4) The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 7 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 2,500 | $0.00 | 0 | D | $27.50 · — to 2032-01-31 | 2,500 Common Stock | (F5) The stock option is fully vested and exercisable. |
| 8 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 1,250 | $0.00 | 3,750 | D | $22.40 · — to 2033-01-31 | 1,250 Common Stock | (F6) One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 9 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 1,625 | $0.00 | 17,875 | D | $20.46 · — to 2035-01-31 | 1,625 Common Stock | (F7) One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. |